Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Protara Therapeutics

Protara Therapeutics (NASDAQ: TARA) insider transactions

In the twelve months to 10 November 2026, executives and directors of Protara Therapeutics reported 3 open-market sales of 239,419 shares ($1.0m) and 0 open-market purchases, by 2 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Protara Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
30 June 2026Shefferman JesseCEO and PresidentGift−14,000—707,832Form 4
30 June 2026Shefferman JesseCEO and PresidentGift−7,000—700,832Form 4
30 June 2026Shefferman JesseCEO and PresidentGift−4,000—696,832Form 4
30 June 2026Shefferman JesseCEO and PresidentGift−5,000—691,832Form 4
29 June 2026Shefferman JesseCEO and PresidentOption exercise+215,687$1.91937,519Form 4
29 June 2026Shefferman JesseCEO and PresidentOpen-market sale−215,687$4.09721,832Form 4
2 June 2026Conkling WilliamChief Commercial OfficerShares withheld for tax−6,008$4.3469,992Form 4
8 April 2026Zummo JacquelineChief R&D OfficerOpen-market sale−1,134$5.4094,827Form 4
1 April 2026Zummo JacquelineChief R&D OfficerOpen-market sale−22,598$5.2695,961Form 4
26 January 2026Fabbio PatrickChief Financial OfficerShares withheld for tax−3,261$6.6764,115Form 4
26 January 2026Fry HannahVP, ControllerShares withheld for tax−1,457$6.6742,723Form 4
26 January 2026Zummo JacquelineChf Scientific Operations OffShares withheld for tax−3,724$6.67118,559Form 4
26 January 2026Shefferman JesseCEO and PresidentShares withheld for tax−8,732$6.671,021,832Form 4
20 January 2026Fry HannahVP, ControllerShares withheld for tax−2,132$5.6044,180Form 4
20 January 2026Zummo JacquelineChf Scientific Operations OffShares withheld for tax−6,578$5.60122,283Form 4
20 January 2026Fabbio PatrickChief Financial OfficerShares withheld for tax−3,063$5.6067,376Form 4
20 January 2026Shefferman JesseCEO and PresidentShares withheld for tax−16,322$5.601,030,564Form 4
16 January 2026Zummo JacquelineChf Scientific Operations OffGrant or award+30,000—128,861Form 4
16 January 2026Shefferman JesseCEO and PresidentGrant or award+87,000—1,046,886Form 4
16 January 2026Nicacio Leonardo VianaChief Medical OfficerGrant or award+26,000—78,181Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Protara Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.